Zhou et al. (341), investigated the isolated effect of IFN-α in a cohort study comparing 77 patients with moderate COVID-19 treated with nebulized IFN-α2b (5 mU b.i.d.), oral arbidol (200 mg t.i.d.), or a combination of both.